Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
Equities cratered late in the week as Silicon Valley Bank collapsed. Here is my strategy in light of the SIVB situation. → Read More
Centene Corporation shares are down a third from their all-time high set in August 2022. Click here to see why CNC stock is a Hold. → Read More
Repare Therapeutics has significant collaboration deals with drug giants Roche and Bristol-Myers Squibb. Read more to see an investment analysis of RPTX stock. → Read More
Align Technology's shares have doubled off their November 2022 low. Click here to see why ALGN stock is an avoid now. → Read More
ProPhase Labs has seen huge revenue growth from Covid testing but is rapidly diversifying into other areas. Click here to see our take on PRPH stock. → Read More
Citius Pharmaceuticals' shares should see volatility in the ensuing months as all three of the company’s clinical programs provide catalysts. Find out why CTXR stock is a Hold. → Read More
Prometheus Biosciences stock has tripled since positive mid-stage trial results for its primary candidate. Click here to see our take on RXDX stock. → Read More
Beam Therapeutics develops precision genetic medicines for patients suffering from serious diseases in the US. Click here to read my analysis of BEAM stock. → Read More
Today, we take our first look at Sana Biotechnology, a clinical-stage developmental company. Read more here. → Read More
Fulgent continues to manage through a huge drop off in Covid testing revenues as the pandemic ebbs. Read more to see a full investment analysis of FLGT stock. → Read More
We take a look at small biopharma concern called GlycoMimetics that's focused on developing treatments for disease through inhibition of subset of proteins called selectins. Read more here. → Read More
Exact Sciences stock has soared 35% so far in 2023 thanks largely to an upward revision to Q4 guidance. Click here to see our take on EXAS stock. → Read More
Protalix BioTherapeutics has rallied after its Fabry disease asset PLX-102 received a PDUFA date from the FDA. Here's a full investment analysis on PLX stock. → Read More
Mirati Therapeutics is focused on developing product candidates to address the genetic and immunological promoters of cancer. Read my analysis of MRTX stock. → Read More
Kodiak stock was crushed last Feb. when its lead developmental asset failed to meet its primary end point. Check out if KOD stock is now worthy of a small bet. → Read More
Today, we take a look at microbiome therapeutic developer Seres Therapeutics. It appears headed to its first FDA approval. Click here for our take on MCRB. → Read More
Annovis Bio is advancing its primary drug candidate into late-stage development to potentially treat both Alzheimer's and Parkinson's disease. Find out why ANVS stock is a Hold. → Read More
Cidara has an impressive set of collaboration deals with larger drug firms and its first FDA approval is on the near-term horizon. See why I'm bullish on CDTX stock. → Read More
Design Therapeutics is an early clinical-stage biopharmaceutical concern. Read more to see my thoughts on DSGN and my recommendation. → Read More
Today, we revisit a small cap oncology concern called Immutep for the first time in two years. Read my investment analysis of IMMP stock. → Read More